Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

This case report documents a 33-year-old male with autoimmune polyglandular syndrome type 2, including diabetes mellitus type 1, Hashimoto thyroiditis, adrenal insufficiency, and Crohn's disease, highlighting the ongoing difficulties in managing multiple autoimmune conditions.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study found that superficial cryotherapy significantly increased hair density and thickness in treated eyebrows compared to untreated controls after 5 months in patients with alopecia areata.

This case report describes a 56-year-old woman with rheumatoid arthritis who developed alopecia universalis during treatment with the TNF inhibitor adalimumab, with no hair regrowth after stopping the medication.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This article shares a case of Satoyoshi syndrome that was misdiagnosed as vitamin D-dependent rickets for several years.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

This case report describes a patient in whom vitiligo was induced by diphenylcyclopropenone treatment for alopecia universalis, highlighting the potential overlap of susceptibility genes between the two conditions.

In this case study, the progression of alopecia universalis in a Japanese man was linked to the involvement of Th1 and Th17 cells, suggesting an autoimmune mechanism.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

This article does not contain an abstract and presents no new clinical findings, instead discussing prior cases and literature on infant alopecia universalis and the potential role of topical PUVA therapy.

This article discusses the potential role of azelaic acid in treating dermatological disorders with reticulate pigmentation and reports no new clinical results; larger trials are needed for better understanding.

This article reviews alopecia treatment and reports a case where hair regrew rapidly with prednisolone, but fell out again after stopping the medication; no new results are presented.

This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.

This case study reports significant hair regrowth in a 61-year-old woman with alopecia universalis after she was treated with hydroxychloroquine for accompanying granuloma annulare.

This study presents a reported case where dupilumab treatment for atopic dermatitis led to improvement in alopecia universalis.

This study observed that vitamin D therapy may help manage alopecia areata, totalis, and universalis, with promising hair regrowth in some pediatric cases, though further trials are needed.

This case report describes successful treatment of alopecia universalis associated with severe hyperthyroidism using azathioprine and hydroxychloroquine after poor response to oral steroid therapy.

This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This case report highlights a severe kidney injury linked to the combined use of ciclosporin and simvastatin in a patient treated for alopecia universalis.

In this case study, a 21-year-old man with alopecia universalis experienced temporary hair regrowth after treatment with recombinant human bone morphogenetic protein-2 following a tibial fracture.

This case report presents a 28-year-old woman with alopecia universalis and macular dystrophy, highlighting a potential new linkage between these conditions without previously identified associated genes.

This study describes the first reported case of a 37-year-old woman developing alopecia universalis after switching from rituximab to ocrelizumab for progressive multiple sclerosis, suggesting that ocrelizumab may trigger autoimmune reactions in immunocompromised patients.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.